If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
138
results.
Updated on
14/10/2025 [07:12:00]
Results 50 to 75 of 138
Absstract of: WO2025198810A1
Disclosed are systems and techniques for glucose sensing. For example, an example of a process can include transmitting, by at least one transmitter into living tissue, a first signal with a first wavelength, a second signal with a second wavelength, and a third signal with a third wavelength to produce an acoustic response from the living tissue. The first wavelength has a first correlation with the blood glucose concentration, the second wavelength has a second correlation with the blood glucose concentration, and the third wavelength has a third correlation with the blood glucose concentration. The process can include receiving, by at least one receiver, a response signal of the acoustic response. The process can include determining, by at least one processor, the blood glucose concentration based on a photoacoustic spectrum of the response signal.
Absstract of: US2025295854A1
Exemplary embodiments may attempt to account for more substantial deviations in a user's basal insulin needs and reduce or eliminate glucose level excursions that may result from such deviations more quickly than conventional insulin pump systems. The exemplary embodiments may rely upon a user's recent basal insulin delivery history to establish a current estimate of the user's basal insulin needs. Exemplary embodiments may calculate a reliability metric for a TDI value that reflects that degree of variance in TDI value for a user over a recent period, such as over multiple days or weeks. The reliability indicator may be used to adjust the TDI value that is used to establish a user's daily basal insulin needs and hourly basal insulin needs. In determining a user's basal insulin needs, the exemplary embodiments may not only look to recent basal insulin deliveries but also may account for correction boluses and/or meal boluses.
Absstract of: EP4620384A2
User interfaces for glucose insight presentation are leveraged. A glucose monitoring application is configured to process glucose measurements to determine one or more glucose insights, e.g., about a user's glucose. The glucose measurements, for example, may be obtained from a glucose monitoring device that collects glucose measurements of the user at predetermined intervals, e.g., every five minutes. The glucose monitoring application configures a user interface, based on configuration data, to present one or more visual elements representative of the one or more glucose insights. For example, the glucose monitoring application may configure the user interface to include a visual element in the form of a color field which represents whether the user's current glucose measurement (e.g., the most recent glucose measurement obtained from the glucose monitoring device) is below, within, or above a glucose range.
Absstract of: EP4621804A2
Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.
Absstract of: EP4620393A1
This application discloses a blood glucose monitoring method, a graphical interface, and a related apparatus. In the method, a wearable device collects a PPG signal of a user used to reflect blood glucose of the user within a time period, removes a low-quality PPG signal collected when the user is affected by an external factor, and determines, based on a reserved PPG signal, a quantity of occurrences of a blood glucose abnormality and/or a blood glucose risk of the user within the time period. It can be learned that, when data used to reflect the blood glucose of the user is collected, the user may be affected by the external factor, and the device may remove the PPG signal collected when the user is affected by the external factor. In this way, a status of the user does not need to be considered in a blood glucose monitoring process, thereby achieving an effect of unperceived blood glucose monitoring.
Absstract of: LU600638B1
The present invention discloses a construction system for a cardiovascular disease risk prediction model for patients with type 2 diabetes, comprising a bottom base, a mounting slot, a prediction system, a data collection and preprocessing module, a feature selection and extraction module, a model construction module, amodel evaluation and validation module, a user interaction module, a speaker, and a display. The bottom base is provided with a mounting slot, within the mounting slot the prediction system is arranged. The present invention is designed as an integrated and comprehensive construction system for a cardiovascular disease risk prediction model for patients with type 2 diabetes. Based on the results of multifactorial Logistic regression analysis, a highly accurate risk prediction model is constructed. Furthermore, statistical methods are employed to validate the predictive performance of the model, providing a novel tool for identifying high-risk individuals for cardiovascular disease among patients with type 2 diabetes. Additionally, the present invention not only considers traditional risk factors but also incorporates biochemical indicators such as serum albumin, serum uric acid, and parathyroid hormone.
Absstract of: AU2025223845A1
Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol- responsive active area to detect glucose and ethanol in vivo. Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol- responsive active area to detect glucose and ethanol in vivo. ug u l t i p l e e n z y m e s m a y b e p r e s e n t i n o n e o r m o r e a c t i v e a r e a s o f a n e l e c t r o c h e m i c a l u g a n a l y t e s e n s o r f o r d e t e c t i n g o n e o r m o r e d i f f e r e n t a n a l y t e s n p a r t i c u l a r , a n a n a l y t e s e n s o r m a y c o m p r i s e a s e n s o r t a i l c o n f i g u r e d f o r i n s e r t i o n i n t o a t i s s u e a n d o n e o r m o r e w o r k i n g e l e c t r o d e s h a v i n g a g l u c o s e - r e s p o n s i v e a c t i v e a r e a a n d a n e t h a n o l - r e s p o n s i v e a c t i v e a r e a t o d e t e c t g l u c o s e a n d e t h a n o l i n v i v o
Absstract of: AU2025223826A1
A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. The plunger body is configured to be decoupled from the first position and to be moved to a second position in an injecting direction. The sensor module is coupled to one end portion of the plunger body to be moved integrally with the plunger body as the plunger body being moved toward the second position. An adhesive layer is attached to a lower surface of the sensor module to attach the sensor module to the human body, and is configured to be moved together with the sensor module as the plunger body being moved toward the second position. A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. T
Absstract of: US2025288224A1
Systems and methods of optimizing glucose medication dosages are based on modeling a patient's glucose lowering response using historical glucose data. The model is actively updated to account for changes in the patient's medication treatments and physiological conditions based on real-time or near real-time glucose measurements from the patient. The system can analyze various dosages of insulin based on the patient's current therapy and the model to determine an optimized dosage. Also disclosed is a system and method for retrieving a patient's current medication therapies from medical records using an automated system. Also disclosed are methods of implementing remotely-updatable limitations for medication optimization algorithms.
Absstract of: WO2025194017A1
Systems and methods of optimizing glucose medication dosages are based on modeling a patient's glucose lowering response using historical glucose data. The model is actively updated to account for changes in the patient's medication treatments and physiological conditions based on real-time or near real-time glucose measurements from the patient. The system can analyze various dosages of insulin based on the patient's current therapy and the model to determine an optimized dosage. Also disclosed is a system and method for retrieving a patient's current medication therapies from medical records using an automated system. Also disclosed are methods of implementing remotely-updatable limitations for medication optimization algorithms.
Absstract of: WO2025189236A1
Some embodiments relate to devices and methods for determining a measure of glucose in a first substance. An example device may comprise: a light source configured to emit near-infrared light at a first wavelength at a first quantity of the first substance, the first substance comprising a second substance and glucose; a detector, configured to: detect light from the first substance; and provide a signal indicative of an intensity of the detected light; and a controller, configured to: receive the signal from the detector; determine a first measure indicative of the intensity of the detected light from the first substance; determine a measure of glucose in the first substance as a difference between the first measure and a second measure, wherein the second measure is indicative of the intensity of detected light from a second quantity of the second substance when subjected to near-infrared light at the first wavelength; and provide an output based on the determined measure of glucose.
Absstract of: US2024306955A1
The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.
Absstract of: US2025288226A1
Methods, devices, and systems are provided. A method includes receiving sensor data from the glucose sensor, the sensor data being associated with a time window, determining a rate of change distribution of the sensor data, determining a first slope that corresponds to a line of the rate of change distribution, comparing a first slope with a first reference slope, generating, based on comparing the first slope with the first reference slope, an output; and, transmitting the output to a display or a transmitter. Numerous additional features are disclosed.
Absstract of: WO2025193719A1
A system for continuous glucose measurement and spinal cord stimulation provides at least two implantable non-stimulation electrodes configured to continuously monitor at least one physiological parameter on a lead that also includes a plurality of implantable stimulation electrodes. The electrodes are electrically connected to an implantable pulse generator that communicates stimulation instructions and glucose measurement data.
Absstract of: WO2025193785A1
A method of determining a dosage regimen for a glucose disorder includes receiving existing dosage information for a patient at a computing device and receiving, by the computing device, glucose data from a patient using a continuous glucose monitor. Next, the method includes determining a glycemic risk for a time period based on the glucose data, and modifying an existing basal insulin dosage when the glycemic risk indicates an elevated risk of a high glucose level in at least one time period and when the glycemic risk does not indicate an elevated risk of low glucose, and when the existing basal insulin dosage is below a predetermined maximum. Next, the method includes initiating a prandial insulin dose when the glycemic risk indicates an elevated risk of a high glucose level and when the existing basal insulin dosage is at a predetermined maximum.
Absstract of: US2025288225A1
A non-invasive continuous blood glucose concentration (BGC) measurement method and apparatus based on optical coherence tomography angiography (OCTA) are provided. The method includes: performing continuous OCT scanning and imaging on a target tissue region; extracting, based on a depth attenuation characteristic of an OCT signal, a three-dimensional optical scattering coefficient of the target tissue region; generating a three-dimensional microvascular distribution of the target tissue region; accurately distinguishing a blood optical scattering coefficient (BOC) from a tissue optical scattering coefficient (TOC) based on the three-dimensional scattering coefficient and the three-dimensional microvascular distribution; and measuring reference BGCs at two time points through an electrochemical method; and combining the reference BGCs with the BOC and the TOC respectively, thereby achieving continuous measurement of a BGC and an interstitial fluid glucose concentration (IGC). The method and apparatus are based on OCTA to achieve accurate BGC measurement while simultaneously enabling IGC measurement.
Absstract of: US2025288228A1
An analyte sensor configured to compensate for insulin interference includes: a working electrode, including an analyte sensing molecule disposed on the working electrode configured to generate a signal when exposed to an analyte; a processor; and a memory. The memory includes instructions which, when executed by the processor, cause the sensor to: obtain an indication from the pump that the bolus is delivered; in response to the delivery of the bolus, determine at least one of a first electrochemical impedance spectroscopy (EIS) parameter value or a first conductivity value in response to exposure of the working electrode to the analyte; and determine a presence of one or more interferents based on at least one of the first EIS parameter value or the first conductivity value.
Absstract of: EP4616802A2
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: EP4616799A1
Provided is a sensor applicator assembly for a blood glucose monitoring, comprising an applicator, and a body attachment unit disposed inside the applicator and comprising a housing including an upper frame and a lower frame. The lower frame comprises a recess portion formed throughout an entire section along a perimeter direction.
Absstract of: EP4616800A1
An analyte sensor configured to compensate for insulin interference includes: a working electrode, including an analyte sensing molecule disposed on the working electrode configured to generate a signal when exposed to an analyte; a processor; and a memory. The memory includes instructions which, when executed by the processor, cause the sensor to: obtain an indication from the pump that the bolus is delivered; in response to the delivery of the bolus, determine at least one of a first electrochemical impedance spectroscopy (EIS) parameter value or a first conductivity value in response to exposure of the working electrode to the analyte; and determine a presence of one or more interferents based on at least one of the first EIS parameter value or the first conductivity value.
Absstract of: LU600551B1
The present invention relates to the field of medical waste treatment, and provides an anti-stabbing collection sharps container for insulin injection needles, including a support frame with a collection box arranged inside, a top cover being fixed on the top of the collection box, and a flip cover being rotatably mounted inside the top cover; an auxiliary assembly arranged on the flip cover for assisting in the disassembly of needles, the auxiliary assembly including a hopper, the outer wall of the hopper being fixed on the flip cover, a sealing plate being rotatably mounted inside the hopper, two sliders symmetrically arranged in the left-right direction being slidably mounted inside the hopper, clamping blocks being fixed on the upper surfaces of the sliders, arc-shaped grooves being disposed inside the clamping blocks, and a plurality of teeth being fixed inside the clamping blocks.
Absstract of: WO2025188313A1
A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.
Absstract of: WO2025189059A1
A method and system for establishing and executing a dynamic titration protocol for administration of an antidiabetic is disclosed. The method may include establishing an initial titration protocol and then applying an aggressiveness level to the initial titration protocol to obtain an initial use titration protocol. The initial use titration protocol may then be executed with a patient and glucose monitoring data may be received from the patient. The monitoring data may be used to perform a failsafe monitoring procedure and a revised aggressiveness level and titration protocol may be determined based on the results of the failsafe monitoring.
Absstract of: WO2025188997A1
Disclosed herein are system, method, and computer program product embodiments for generating determining overnight hypoglycemia risk by estimating the likelihood of a hypoglycemic event occurring over a specified period of time, namely overnight. The disclosure describes utilizing two key aspects: factors that can disturb glucose levels are much less likely to occur overnight, and bedtime is a convenient and beneficial time for the patient to check for and mitigate their risk of hypoglycemia overnight.
Nº publicación: WO2025188465A1 12/09/2025
Applicant:
ARTILUX INC [US]
ARTILUX, INC
Absstract of: WO2025188465A1
Described herein are systems and methods for non-invasive glucose detection using an optical sensing apparatus. The optical sensing apparatus comprises one or more single-photon avalanche diodes (SPADs) and one or more processors. The one or more SPADs may be configured to receive light pulses having one or more wavelengths that have interacted with biological tissues over a plurality of time cycles and convert the light pulses into a plurality of electrical signals. Each of the one or more SPADs may comprise an absorption region formed on a substrate, wherein the absorption region comprises germanium or germanium containing tin, and wherein the substrate comprises silicon. The one or more processors may be configured to identify, for each of the plurality of time cycles, particular time slots representing a time duration that each of the light pulses has interacted with glucose molecules and determine one or more characteristics of glucose molecules.
BOPI
Electronic site
